Your session is about to expire
← Back to Search
P53MVA + Pembrolizumab for Ovarian Cancer
Study Summary
This trial studies how well a modified virus vaccine and pembrolizumab work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can care for myself and doctors expect me to live at least 3 more months.I have had up to 4 chemotherapy treatments for my recurring cancer.I haven't had cancer treatment in the last 4 weeks.I am currently being treated for an infection.My family has a history of Li-Fraumeni syndrome.I have a history of HIV, hepatitis B, hepatitis C, or active TB.I have had or currently have lung inflammation treated with steroids.I have another cancer that is getting worse or was treated in the last 3 years.I do not have a history of serious heart conditions or uncontrolled high blood pressure.I had radiotherapy less than 3 weeks before starting the study treatment.I don't have any health issues that could affect the study's results.My cancer has spread to my brain or its coverings.I have not received a live vaccine in the last 30 days.My ovarian, peritoneal, or fallopian tube cancer has returned or worsened within 6 months after platinum chemotherapy.My cancer has a p53 mutation or shows high levels of p53.I have received treatment with specific medications before.I have an immune system disorder or have taken steroids in the past week.I am not pregnant, not breastfeeding, and can follow birth control guidelines if needed.
- Group 1: Treatment (pembrolizumab, p53MVA)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are being evaluated in this experiment?
"Currently, this trial is not seeking any new patients. Posted on February 1st 2018 and last updated September 28th 2022, there are several other treatments with open studies for fallopian tube carcinoma; 3374 trials to be exact. Moreover, 975 clinical trials featuring Pembrolizumab are presently admitting participants."
What is the current regulatory status of Pembrolizumab?
"A score of 2 was given to Pembrolizumab for its safety rating, as clinical data has verified that it is safe, but there have not been any trials demonstrating efficacy."
Has Pembrolizumab been investigated in any additional research projects?
"At this time, there are 975 medical trials investigating pembrolizumab. Of those active studies, 122 have progressed to the third phase of clinical testing. The majority of these experiments take place in Houston, Texas but 35804 other facilities are conducting research into this treatment as well."
Are there still opportunities for patients to participate in this research?
"As of this moment, enrolling patients into the trial is not available. It was initially posted on February 1st 2018 and last updated September 28th 2022. As an alternative, there are presently 3374 clinical trials for fallopian tube carcinoma actively recruiting and 975 studies that utilize Pembrolizumab in search of participants."
In what capacity is Pembrolizumab usually employed?
"Pembrolizumab is frequently used as a form of treatment for cancerous neoplasms. Additionally, it can be employed to treat issues like advanced melanoma, microsatellite instability-high tumours, and the recurrence of symptoms after chemotherapy."
Share this study with friends
Copy Link
Messenger